Tradestie Institutional Equity Comparison Engine

GLUE vs RGNX โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

GLUE Overall Edge

GLUE Captures Institutional Edge (2โ€“2 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Monte Rosa Therapeutics, Inc. Common Stock (GLUE) driven by superior Valuation, Options & Structure while RGNX counters with relative strength in Growth & Margin, Momentum & Technical. Fundamentally, GLUE trades at 10.0x Forward P/E with -214.5% operating margin (+325.8% YoY revenue) versus RGNX at N/M Forward P/E and -120.4% operating margin (-69.2% YoY). In options structure, GLUE sits in BREAKDOWN (16th %ile IV; Dealer Gamma Walls on Pro) against RGNX sits in BREAKDOWN (52nd %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner GLUE
GLUE 10.0x vs RGNX N/M Fwd P/E
Growth & Margin Winner RGNX
Op Margin -214.5% vs -120.4% ยท YoY +325.8% vs -69.2%
Momentum & Technical Winner RGNX
1Y -35.9% vs -36.0% ยท 52W Pos 1% vs 19%
Options & Structure Winner GLUE
BREAKDOWN (16th %ile IV) vs BREAKDOWN (52nd %ile IV)
GLUE NASDAQ
Monte Rosa Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$9.18
-2.03% 1D
Market Cap $795.5M
1M Return -5.75%
1Y Return -35.89%
Forward P/E 10.0x
Unified AI Score
44.2 / 100 HOLD
Tech 32.0 Fund 51.0 Flow 70.0 Mom 60.0
RGNX NASDAQ
REGENXBIO Inc.
Biological Products, (No Disgnostic Substances)
$7.45
-2.49% 1D
Market Cap $500.9M
1M Return +7.58%
1Y Return -36.0%
Forward P/E N/M
Unified AI Score
45.3 / 100 HOLD
Tech 36.0 Fund 44.0 Flow 69.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: GLUE -35.89% RGNX -36.0% Spread: +0.11 pp (GLUE Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period GLUE Revenue RGNX Revenue GLUE Op. Margin RGNX Op. Margin Margin Edge
FY2018 N/A $220M N/A 40.3% RGNX
FY2019 N/A $40M N/A -422.9% RGNX
FY2020 N/A $150M N/A -77.1% RGNX
FY2021 N/A $470M N/A 34.0% RGNX
FY2022 N/A $110M N/A -233.2% RGNX
FY2023 N/A $90M N/A -297.1% RGNX
FY2024 $80M $80M -107.3% -280.0% GLUE
FY2025 $120M $170M -43.8% -94.6% GLUE

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: GLUE (6) vs RGNX (4)
Institutional Metric GLUE RGNX Criterion Row Winner
Market Capitalization Scale $795.5M $500.9M Larger Scale GLUE
Trailing P/E Ratio Valuation 10.0x N/M Lower Multiple GLUE
Forward P/E Ratio Valuation 10.0x N/M Lower Multiple GLUE
Revenue Growth (YoY) Growth +325.8% -69.2% Higher Growth GLUE
Operating Margin (TTM) Profitability -214.5% -120.4% Higher Margin RGNX
Net Profit Margin Profitability -186.2% -113.9% Higher Margin RGNX
Return on Equity (ROE) Capital Efficiency -35.3% -113.2% Higher ROE GLUE
52-Week Range Position Momentum 1% ($9โ€“$26) 19% ($5โ€“$16) Stronger Trend RGNX
Beta / 30D Volatility Risk Regime 0.95ฮฒ ยท 53% Vol 1.82ฮฒ ยท 76% Vol Lower Realized Risk GLUE
Unified Institutional Score Composite Signal 44.2 / 100 (HOLD) 45.3 / 100 (HOLD) Higher Composite RGNX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full GLUE vs RGNX Buy Guide
GLUE BREAKDOWN
85d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 16th %ile
IV Regime Compressed (<25th %ile)
Live GLUE Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
RGNX BREAKDOWN
91d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 52nd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live RGNX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither GLUE nor RGNX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.